Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 87 results for bevacizumab

  1. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

    Technology appraisal guidance
    Last updated
    26 October 2023
    View recommendations

    Sections for TA274

  2. Aflibercept for treating diabetic macular oedema (TA346)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA346

  3. Brolucizumab for treating wet age-related macular degeneration (TA672)

    Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    3 February 2021
    View recommendations

    Sections for TA672

  4. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development [GID-TA11161] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA409

  6. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

    In development [GID-TA10571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  7. Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on health-related quality of life.

    TA263/1 Question Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on...

    Research recommendation
    Published
    9 June 2015

  8. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]

    In development [GID-TA10907] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  10. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    13 May 2020
    View recommendations

    Sections for TA628

  11. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

    Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer in adults after complete tumour resection.

    Technology appraisal guidance
    Published
    19 January 2022
    View recommendations

    Sections for TA761

  12. Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.

    differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior...

    Research recommendation
    Published
    9 June 2015

  13. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

    Awaiting development [GID-TA11076] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    28 March 2024
    View recommendations

    Sections for TA962